Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2015 08:30 ET | Source: Zogenix, Inc.

Zogenix Announces New Efficacy Data From a Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome

New data presented at European Paediatric Neurology Society Congress in Vienna, Austria includes 10 patients who continued treatment with low-dose fenfluramine for Dravet syndrome following the...
May 11, 2015 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results

SAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
May 04, 2015 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11

SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
April 27, 2015 16:05 ET | Source: Zogenix, Inc.

Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline

SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
April 24, 2015 13:00 ET | Source: Zogenix, Inc.

Zogenix Closes Sale of Zohydro(R) ER Business to Pernix

SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...